CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

IF 5.1 2区医学 Q1 HEMATOLOGY

British Journal of Haematology Pub Date : 2024-12-25 DOI:10.1111/bjh.19967

Chezi Ganzel, Avraham Frisch, Ofir Wolach, Yakir Moshe, Baher Krayem, Neta Dor, Etti Broide, Emmanuel Benayoun, Jacob M Rowe, Yishai Ofran

引用次数: 0

Abstract

This pilot study evaluated CPX-351 in adults with newly diagnosed, favourable-intermediate risk, FLT3-ITD-negative AML. Twenty patients received CPX-351 for induction, with six also receiving gemtuzumab ozogamicin (GO). The complete response rate was 95%, with 42% achieving flow-based minimal residual disease (MRD) negativity post-induction. The 18-month leukaemia-free and overall survival estimates were 80% and 95% respectively. Adding GO appeared safe without prolonged cytopenias. Subclinical cardiotoxicity was observed in 25% of patients. The study demonstrated CPX-351's feasibility, with response and MRD-negativity rates comparable to standard '7 + 3' induction.

查看原文本刊更多论文

CPX-351 +/- gemtuzumab ozogamicin作为新诊断、有利-中等风险、FLT3-ITD阴性的AML成人患者的诱导治疗：一项试点研究

这项初步研究评估了CPX-351在新诊断、有利-中等风险、flt3 - itd阴性AML成人患者中的应用。20名患者接受了CPX-351诱导，6名患者也接受了吉妥珠单抗ozogamicin （GO）。完全缓解率为95%，诱导后42%达到基于血流的最小残留病（MRD）阴性。18个月无白血病生存率和总生存率分别为80%和95%。添加氧化石墨烯是安全的，没有延长的细胞减少。25%的患者出现亚临床心脏毒性。该研究证明了CPX-351的可行性，其反应率和mrd阴性率与标准的“7 + 3”诱导相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.